15-Lipoxygenase Metabolites of Docosahexaenoic Acid Inhibit Prostate Cancer Cell Proliferation and Survival

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  O'Flaherty, Joseph T ^a   Hu, Yungping ^a   Wooten, Rhonda E ^a   Horita, David A ^a   Samuel, Michael P ^a   Thomas, Michael J ^a   Sun, Haiguo ^a   Edwards, Iris J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10,17 DIHYDROXY DOCOSAHEXAENOIC ACID; 15 HYDROPEROXY EICOSATETRAENOIC ACID; 15 HYDROXY EICOSATETRAENOIC ACID; 17 HYDROPEROXY DOCOSAHEXAENOIC ACID; 17 HYDROXY DOCOSAHEXAENOIC ACID; 5,15 DIHYDROXY EICOSATETRAENOIC ACID; 7,17 DIHYDROXY DOCOSAHEXAENOIC ACID; 8,15 DIHYDROXY EICOSATETRAENOIC ACID; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONIC ACID DERIVATIVE; DOCOSAHEXAENOIC ACID; DRUG METABOLITE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SYNDECAN 1; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION;

APOPTOSIS; ARACHIDONATE 15-LIPOXYGENASE; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOCOSAHEXAENOIC ACIDS; HUMANS; MALE; PPAR GAMMA; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; SYNDECAN-1;

EID: 84866673758     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045480     Document Type: Article

References (61)

1. Norrish AE, Skeaff CM, Arribas GL, Sharpe SJ, Jackson RT, (1999) Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. Br J Cancer 81: 1238-1242.
2. Terry P, Lichtenstein P, Feychting M, Ahlbom A, Wolk A, (2001) Fatty fish consumption and risk of prostate cancer. Lancet 357: 1764-1766.
3. Yang YJ, Lee SH, Hong SJ, Chung BC, (1999) Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia. Clin Biochem 32: 405-409.
4. Mamalakis G, Kafatos A, Kalogeropoulos N, Andrikopoulos N, Daskalopulos G, et al. (2002) Prostate cancer vs hyperplasia: relationships with prostatic and adipose tissue fatty acid composition. Prostaglandins Leukot Essent Fatty Acids 66: 467-477.
5. Freeman VL, Meydani M, Hur K, Flanigan RC, (2004) Inverse association between prostatic polyunsaturated fatty acid and risk of locally advanced prostate carcinoma. Cancer 101: 2744-2754.
6. Rose DP, Connolly JM, (1991) Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate 18: 243-254.
7. Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, et al. (2006) Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res 12: 4662-4670.
8. Berquin IM, Min Y, Wu R, Wu J, Perry D, et al. (2007) Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest 117: 1866-1875.
9. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A, (2004) Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 79: 935-945.
10. Berquin IM, Edwards IJ, Kridel SJ, Chen YQ, (2011) Polyunsaturated fatty acid metabolism in prostate cancer. Cancer Metastasis Rev 30: 295-309.
11. Edwards IJ, Berquin IM, Sun H, O'Flaherty J T, Daniel LW, et al. (2004) Differential effects of delivery of omega-3 fatty acids to human cancer cells by low-density lipoproteins versus albumin. Clin Cancer Res 10: 8275-8283.
12. Hu Y, Sun H, Owens RT, Gu Z, Wu J, et al. (2010) Syndecan-1-dependent suppression of PDK1/Akt/bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer. Neoplasia 12: 826-836.
13. Chung BH, Mitchell SH, Zhang JS, Young CY, (2001) Effects of docosahexaenoic acid and eicosapentaenoic acid on androgen-mediated cell growth and gene expression in LNCaP prostate cancer cells. Carcinogenesis 22: 1201-1206.
14. Kelavkar U, Lin Y, Landsittel D, Chandran U, Dhir R, (2006) The yin and yang of 15-lipoxygenase-1 and delta-desaturases: dietary omega-6 linoleic acid metabolic pathway in prostate. J Carcinog 5: 9.
15. Kelavkar UP, Cohen C, Kamitani H, Eling TE, Badr KF, (2000) Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging. Carcinogenesis 21: 1777-1787.
16. Spindler SA, Sarkar FH, Sakr WA, Blackburn ML, Bull AW, et al. (1997) Production of 13-hydroxyoctadecadienoic acid (13-HODE) by prostate tumors and cell lines. Biochem Biophys Res Commun 239: 775-781.
17. Brash AR, Jisaka M, Boeglin WE, Chang MS, Keeney DS, et al. (1999) Investigation of a second 15S-lipoxygenase in humans and its expression in epithelial tissues. Adv Exp Med Biol 469: 83-89.
18. Wecksler AT, Kenyon V, Deschamps JD, Holman TR, (2008) Substrate specificity changes for human reticulocyte and epithelial 15-lipoxygenases reveal allosteric product regulation. Biochemistry 47: 7364-7375.
19. Jack GS, Brash AR, Olson SJ, Manning S, Coffey CS, et al. (2000) Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 31: 1146-1154.
20. Shappell SB, Manning S, Boeglin WE, Guan YF, Roberts RL, et al. (2001) Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia 3: 287-303.
21. Kelavkar UP, Parwani AV, Shappell SB, Martin WD, (2006) Conditional expression of human 15-lipoxygenase-1 in mouse prostate induces prostatic intraepithelial neoplasia: the FLiMP mouse model. Neoplasia 8: 510-522.
22. Suraneni MV, Schneider-Broussard R, Moore JR, Davis TC, Maldonado CJ, et al. (2010) Transgenic expression of 15-lipoxygenase 2 (15-LOX2) in mouse prostate leads to hyperplasia and cell senescence. Oncogene 29: 4261-4275.
23. Kelavkar UP, Nixon JB, Cohen C, Dillehay D, Eling TE, et al. (2001) Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. Carcinogenesis 22: 1765-1773.
24. Bhatia B, Maldonado CJ, Tang S, Chandra D, Klein RD, et al. (2003) Subcellular localization and tumor-suppressive functions of 15-lipoxygenase 2 (15-LOX2) and its splice variants. J Biol Chem 278: 25091-25100.
25. Tang DG, Bhatia B, Tang S, Schneider-Broussard R, (2007) 15-lipoxygenase 2 (15-LOX2) is a functional tumor suppressor that regulates human prostate epithelial cell differentiation, senescence, and growth (size). Prostaglandins Other Lipid Mediat 82: 135-146.
26. Hsi LC, Wilson LC, Eling TE, (2002) Opposing effects of 15-lipoxygenase-1 and-2 metabolites on MAPK signaling in prostate. Alteration in peroxisome proliferator-activated receptor gamma. J Biol Chem 277: 40549-40556.
27. Kelavkar UP, Cohen C, (2004) 15-lipoxygenase-1 expression upregulates and activates insulin-like growth factor-1 receptor in prostate cancer cells. Neoplasia 6: 41-52.
28. Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, et al. (2001) 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 61: 497-503.
29. Subbarayan V, Krieg P, Hsi LC, Kim J, Yang P, et al. (2006) 15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma. Oncogene 25: 6015-6025.
30. Ghosh J, Myers CE, (1997) Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem Biophys Res Commun 235: 418-423.
31. Amin M, Jeyaganth S, Fahmy N, Begin LR, Aronson S, et al. (2008) Dietary habits and prostate cancer detection: a case-control study. Can Urol Assoc J 2: 510-515.
32. Astorg P, (2005) [Dietary fatty acids and colorectal and prostate cancers: epidemiological studies]. Bull Cancer 92: 670-684.
33. Williams CD, Whitley BM, Hoyo C, Grant DJ, Iraggi JD, et al. (2011) A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer. Nutr Res 31: 1-8.
34. O'Flaherty JT, Rogers LC, Paumi CM, Hantgan RR, Thomas LR, et al. (2005) 5-Oxo-ETE analogs and the proliferation of cancer cells. Biochim Biophys Acta 1736: 228-236.
35. Pham H, Banerjee T, Nalbandian GM, Ziboh VA, (2003) Activation of peroxisome proliferator-activated receptor (PPAR)-gamma by 15S-hydroxyeicosatrienoic acid parallels growth suppression of androgen-dependent prostatic adenocarcinoma cells. Cancer Lett 189: 17-25.
36. Vang K, Ziboh VA, (2005) 15-lipoxygenase metabolites of gamma-linolenic acid/eicosapentaenoic acid suppress growth and arachidonic acid metabolism in human prostatic adenocarcinoma cells: possible implications of dietary fatty acids. Prostaglandins Leukot Essent Fatty Acids 72: 363-372.
37. Burdge GC, Wootton SA, (2002) Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. Br J Nutr 88: 411-420.
38. Edwards IJ, Sun H, Hu Y, Berquin IM, O'Flaherty JT, et al. (2008) In vivo and in vitro regulation of syndecan 1 in prostate cells by N-3 polyunsaturated fatty acids. J Biol Chem 283: 18441-18449.
39. O'Flaherty JT, Thomas MJ, (1985) Effect of 15-lipoxygenase-derived arachidonate metabolites on human neutrophil degranulation. Prostaglandins Leukot Med 17: 199-212.
40. Butovich IA, Lukyanova SM, Bachmann C, (2006) Dihydroxydocosahexaenoic acids of the neuroprotectin D family: synthesis, structure, and inhibition of human 5-lipoxygenase. J Lipid Res 47: 2462-2474.
41. Butovich IA, (2006) A one-step method of 10,17-dihydro(pero)xydocosahexa-4Z,7Z,11E,13Z,15E,19Z-enoic acid synthesis by soybean lipoxygenase. J Lipid Res 47: 854-863.
42. Chen P, Vericel E, Lagarde M, Guichardant M, (2011) Poxytrins, a class of oxygenated products from polyunsaturated fatty acids, potently inhibit blood platelet aggregation. Faseb J 25: 382-388.
43. Serhan CN, Gotlinger K, Hong S, Lu Y, Siegelman J, et al. (2006) Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J Immunol 176: 1848-1859.
44. Dangi B, Obeng M, Nauroth JM, Teymourlouei M, Needham M, et al. (2009) Biogenic synthesis, purification, and chemical characterization of anti-inflammatory resolvins derived from docosapentaenoic acid (DPAn-6). J Biol Chem 284: 14744-14759.
45. Gonzalez-Periz A, Planaguma A, Gronert K, Miquel R, Lopez-Parra M, et al. (2006) Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. Faseb J 20: 2537-2539.
46. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN, (2003) Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 278: 14677-14687.
47. Hu Y, Sun H, Owens RT, Wu J, Chen YQ, et al. (2009) Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia 11: 1042-1053.
48. Sun H, Berquin IM, Owens RT, O'Flaherty JT, Edwards IJ, (2008) Peroxisome proliferator-activated receptor gamma-mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells. Cancer Res 68: 2912-2919.
49. Sun H, Hu Y, Gu Z, Owens RT, Chen YQ, et al. (2011) Omega-3 fatty acids induce apoptosis in human breast cancer cells and mouse mammary tissue through syndecan-1 inhibition of the MEK-Erk pathway. Carcinogenesis 32: 1518-1524.
50. Hyde CA, Missailidis S, (2009) Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. Int Immunopharmacol 9: 701-715.
51. Kelavkar UP, Hutzley J, McHugh K, Allen KG, Parwani A, (2009) Prostate tumor growth can be modulated by dietarily targeting the 15-lipoxygenase-1 and cyclooxygenase-2 enzymes. Neoplasia 11: 692-699.
52. Matsuyama M, Yoshimura R, (2008) The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer. Biologics 2: 725-732.
53. Pidgeon GP, Lysaght J, Krishnamoorthy S, Reynolds JV, O'Byrne K, et al. (2007) Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev 26: 503-524.
54. Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, et al. (2004) Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev 13: 1710-1716.
55. Calandria JM, Marcheselli VL, Mukherjee PK, Uddin J, Winkler JW, et al. (2009) Selective survival rescue in 15-lipoxygenase-1-deficient retinal pigment epithelial cells by the novel docosahexaenoic acid-derived mediator, neuroprotectin D1. J Biol Chem 284: 17877-17882.
56. Gleissman H, Yang R, Martinod K, Lindskog M, Serhan CN, et al. (2010) Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates. Faseb J 24: 906-915.
57. Poulsen RC, Gotlinger KH, Serhan CN, Kruger MC, (2008) Identification of inflammatory and proresolving lipid mediators in bone marrow and their lipidomic profiles with ovariectomy and omega-3 intake. Am J Hematol 83: 437-445.
58. Serhan CN, Chiang N, Van Dyke TE, (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8: 349-361.
59. Fer M, Dreano Y, Lucas D, Corcos L, Salaun JP, et al. (2008) Metabolism of eicosapentaenoic and docosahexaenoic acids by recombinant human cytochromes P450. Arch Biochem Biophys 471: 116-125.
60. VanRollins M, Baker RC, Sprecher HW, Murphy RC, (1984) Oxidation of docosahexaenoic acid by rat liver microsomes. J Biol Chem 259: 5776-5783.
61. VanRollins M, Murphy RC, (1984) Autooxidation of docosahexaenoic acid: analysis of ten isomers of hydroxydocosahexaenoate. J Lipid Res 25: 507-517.